Clinical Trials with Protons

Non-small Cell Lung Cancer

Head and Neck Cancer (Oropharynx)

Cancer Deaths 2014

Lung and bronchus

159,260


Colon/rectum 50,310}
Breast 40,430} 159,810
Pancreas 39,590}
Prostate 48,029}

Treatment of Locally Advanced NSCLC

Concurrent chemotherapy

Management of tumor motion

 -4D CT simulation and planning
 -Active breath holding
 -Gating



Proton – ITV Approach



____10 Gy _____20 Gy _____35 Gy _____50 Gy _____70 Gy

Treatment of Locally Advanced NSCLC

Concurrent chemotherapy

Management of tumor motion

 -4D CT simulation and planning
 -Active breath holding
 -Gating

Grade 3+ Esophagitis

• IMRT (N=66) 40%

• Proton Therapy (N=62) 6%

Treatment Related Pneumonitis Grade 3+




• Proton Therapy

9%


2 %

Randomized Trial of Photons vs Protons for NSCLC Stage II/III



Adaptive planning; Bayesian statistics


Intensity Modulated Proton Therapy (IMPT)



Modified from Eros Pedroni-PSI Courtesy of Cliff Chao

Beam Scanning


- Deliver many small beams to a tumor using magnetic beam deflection.
- Energy is changed in accelerator to scan each successive layer.



A full set, with a homogenous dose conformed distally <u>and</u> proximally

Pedroni, PSI

Oropharynx - BOT Concurrent Chemoradiation





- 2. Decrease odynophagia
- 3. Decrease N/V
- 4. Decrease weight loss
- 5. No PEG tube
- 6. Decrease xerostomia
- 7. Maintain taste
- 8. Decrease dysphagia



Comparative Trials Protons vs. X-rays (double scattering or IMPT)

 NSCLC : Double scatter protons vs. IMRT (phase II) with Mass General Hospital

- NSCLC: Double scatter protons vs. IMRT (Randomized phase II) with RTOG
- Carcinoma of Oropharynx: IMRT vs. IMPT